

## ACAAI COVID-19 Vaccine Comparison Chart - 8/16/21

Vaccine	Active Ingredient	Dose	Schedule	Age approved	Efficacy against COVID 19	Adverse reactions	Other Ingredients	Contra Indications
Pfizer-BioNTech	m RNA	0.3 ml	2 doses , 21 days apart; 3 <sup>rd</sup> dose for immunocompromised only 28+ days later	12 and up	18-64 years 95.1% 65 and above 94.7 %	Lasted 2-3 days, more adverse reactions after second dose Pain at site, Fatigue, Headache, Myalgia, Chills, Arthralgia Anaphylaxis* (post EUA) Myocarditis/ Pericarditis after second dose	1. Lipids -Including Polyethylene glycol 2. Salts 3. Sugars – Sucrose No preservatives	History of allergic reactions to vaccines / vaccine ingredients including PEG/ Polysorbate
Moderna	m RNA	0.5ml	2 doses , 28 days apart; 3 <sup>rd</sup> dose for immunocompromised only 28+ days later	18 and up	18 to < 65 years – 95.6 % >65 years– 86.4 %	Lasted 2-3 days, more adverse reactions after second dose Pain at site, Fatigue, Headache, Myalgia, Chills, Arthralgia Anaphylaxis* (post EUA) Myocarditis/ Pericarditis after second dose	1. Lipids -Including Polyethylene glycol 2. Salts 3. Sugars – Sucrose No preservatives	History of allergic reactions to vaccines / vaccine ingredients including PEG/ Polysorbate
J and J Vaccine	Ad26 .COV2.S	0.5 ml	1 dose	18 and up	28 days after dose 18- 59 years – 66.1% >60 years -66.2	Injection site pain ,headache fatigue. Reactogenicity were less common ≥60 years of age, in adults ≥18 years it was transient, lasting 1 to 2 days Guillain-Barre syndrome	1. Lipids -Including Polysorbate 80 2. Salts 3. Sugars – cyclodextrin No preservatives	History of allergic reactions to vaccines / vaccine ingredients including PEG/ Polysorbate